FDA clears Pasithea Therapeutics' PAS-004 for phase 2 trial in cutaneous neurofibromas
KTTA•The FDA cleared Pasithea Therapeutics' investigational new drug application for a Phase 2 trial of PAS-004 in NF1-associated cutaneous neurofibromas, enrolling approximately 200 adults.
1. Trial design
The randomized, double-blind, placebo-controlled trial will evaluate three once-daily doses of PAS-004 in approximately 200 adults with NF1-associated cutaneous neurofibromas.
